Retail price regulation and innovation: Reference pricing in the pharmaceutical industry
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical innovation, health and expenditures. The model is based on a dynamic game involving three types of agents: pharmaceutical firms, consumers and a regulatory entity. Pharmaceutical firms choose the leve...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2010
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22361
- Acceso en línea:
- https://doi.org/10.1016/j.jhealeco.2009.11.015
https://repository.urosario.edu.co/handle/10336/22361
- Palabra clave:
- Atorvastatin
Fluindostatin
Hydroxymethylglutaryl coenzyme a reductase inhibitor
Pravastatin
Rosuvastatin
Simvastatin
Drug
Health expenditure
Industrial regulation
Innovation
Modeling
Pharmaceutical industry
Pricing policy
Retailing
Article
Drug cost
Drug industry
Dynamics
Health care cost
Human
Mathematical analysis
Pharmaceutical care
Welfare
Biomedical research
Drug costs
Drug industry
France
Innovation
Me-too
Pharmaceutical laboratories
Reference pricing
investigational
theoretical
economic
Drugs
Models
Models
- Rights
- License
- Abierto (Texto Completo)